Liver cirrhosis is a disease characterized by the loss of functional liver mass. Physiologically based pharmacokinetic (PBPK) modeling was applied to interpret and predict how the interplay among physiological changes in cirrhosis affects pharmacokinetics. However, previous PBPK models under cirrhotic conditions were developed for permeable cytochrome P450 substrates and do not directly apply to substrates of liver transporters. This study characterizes a PBPK model for liver transporter substrates in relation to the severity of liver cirrhosis. A published PBPK model structure for liver transporter substrates under healthy conditions and the physiological changes for cirrhosis are combined to simulate pharmacokinetics of liver transporter substrates in patients with mild and moderate cirrhosis. The simulated pharmacokinetics under liver cirrhosis reasonably approximate observations. This analysis includes meta-analysis to obtain system-dependent parameters in cirrhosis patients and a top-down approach to improve understanding of the effect of cirrhosis on transporter-mediated drug disposition under cirrhotic conditions.

CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 338–349; doi:10.1002/psp4.39; published online on 1 June 2015.

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ☑ PBPK models have been developed to simulate pharmacokinetics of liver transporter substrates and more permeable compounds in healthy individuals. Previously developed PBPK models for individuals with liver cirrhosis assume well-stirred conditions in the liver, hence cannot be reasonably expected to describe the pharmacokinetics of transporter substrates. • WHAT QUESTION DID THIS STUDY ADDRESS? ☑ This study aims at characterizing a PBPK model capable of simulating the pharmacokinetics of liver transporter substrates under cirrhotic conditions by incorporating changes in physiological and biological parameter values. • WHAT THIS STUDY ADDS TO OUR KNOWLEDGE ☑ This study presents the first mechanistic model to estimate the impact of liver cirrhosis on human pharmacokinetics of liver transporter substrates. • HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY THERAPEUTICS ☑ This model can be useful in understanding the changes in liver transporter activity due to cirrhosis, and may aid in predicting systemic and liver exposure for liver transporter substrates under cirrhotic conditions. It can be useful in the design of clinical trials and ultimately for dose adjustments in clinical practice for cirrhotic patients in the future.

Liver cirrhosis is a progressive disease characterized by loss of liver function associated with morphological and physiological changes. The disease progression is usually classified using the Child–Pugh Grades (CP-A (mild), CP-B (moderate), and CP-C (severe)).¹ Physiological changes include loss of functional liver size, decreased cytochrome P450 (CYP) expression, reduced glomerular filtration rate (GFR), and altered cardiac output, hepatic blood flow, hematocrit, and plasma albumin and α1-acid glycoprotein concentrations.¹² The changes may affect systematic and tissue exposure of drugs administered to the patient. Under these pathological conditions, it is necessary to assess drug pharmacokinetics to evaluate potential risk and altered pharmacodynamic effects.

Compared to empirical pharmacokinetic models, physiologically based pharmacokinetic (PBPK) modeling explicitly incorporates physiological information, and can deconvolute multiple mechanisms controlling drug pharmacokinetics.³ As such, PBPK analysis can be invaluable to gain insights into the impact of physiological changes on the pharmacokinetics under disease conditions. PBPK models have been reported in previous publications to predict the pharmacokinetics in patients with liver impairment.⁴⁻⁶ With a "well-stirred" liver model,⁷ these PBPK models successfully extrapolate pharmacokinetics from healthy individuals to patients, in terms of adequately describing the observed plasma pharmacokinetics under different disease conditions.

In addition to the lipophilic compounds that have been mechanistically modeled,⁴⁻⁶ several groups have investigated the pharmacokinetics of liver transporter substrates under mild and moderate liver cirrhosis conditions, prompted by the fact that these compounds are mainly eliminated hepatically.⁸⁻¹² In addition, some liver transporter substrates are developed to treat diseases associated with liver cirrhosis. For example, bosentan¹³ is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension, which has a higher prevalence
PBPK for Transporter Substrates in Liver Cirrhosis
Li et al.

The model is implemented in MATLAB (v. 2010b, MathWorks, Natick, MA). The fitted parameters are estimated by minimizing the squared error between log10 transformed data and simulations, using the pattern search optimizer in the MATLAB Global Optimization Toolbox.

Local sensitivity analysis
Local sensitivity analyses of the area under curve (AUCplasma, 0 → t and AUCliver, 0 → t) were conducted as described previously where each parameter (for healthy individuals) is raised by 1% with respect to its value in the simulations. Sensitivity coefficients are normalized to both the parameter value and the model output. To keep the blood flow balanced, when the blood flow to any other organ is increased, the lung blood flow and the cardiac output will be raised accordingly. Similarly, if the lung blood flow or the cardiac output is raised, blood flow in all other organs will be increased. If liver arterial blood, gut blood, or spleen blood flow is raised, both lung blood flow and liver venous blood flow will be increased, and vice versa. To analyze the sensitivity to the liver mass (for healthy individuals the functional liver mass is the same as the physical liver mass), CLpass, CLscl, CLmet, and CLbile are raised 1% together with the liver volume. Only parameters with normalized sensitivity coefficients greater than 0.3 or less than −0.3 are reported.

Physiological parameters for cirrhosis
Meta-analysis. We used the same source literature reporting changes for physiological parameter values as published before. For the functional liver size analysis, only datasets classified using the Child–Pugh system are selected. Studies using functional assays (e.g., galactose elimination capacity or hepatic sorbitol clearance) are not included because the data may be confounded by blood flow, or the expression level of metabolic enzymes. The physiological changes associated with liver cirrhosis are represented as the ratios of mean reported values between the disease group and the healthy group (except for RA). To estimate the population mean of the ratios based on the individual studies, one could pool the measured physiological parameter values, and take the ratios between population means of healthy and cirrhosis groups. However, the measurement techniques for these parameters are different from study to study, and as such it may not be proper to pool these measurements directly. To bypass this challenge, instead of pooling the measurements we take the ratios of individually reported values and pool the ratios to estimate the population mean of the ratios.

The ratios are calculated as:

$$R_{i} = \frac{x_{\text{cirrhosis}, i}}{x_{\text{healthy}, i}}$$

where \(x_{\text{cirrhosis}}\) and \(x_{\text{healthy}}\) represent the reported sample mean values for the cirrhosis group and the healthy group in study \(i\). The standard error (SE) of the ratios in each individual study is calculated through the propagation of uncertainty:

$$SE_{R_{i}} = \frac{x_{\text{cirrhosis}, i}}{\sqrt{x_{\text{cirrhosis}, i}^2 + x_{\text{healthy}, i}^2}}$$
\[ SE^2 = \left( \frac{X_{\text{cirrhosis},i}}{X_{\text{healthy},i}} \right)^2 \cdot \left[ \frac{SE_{\text{cirrhosis},i}}{X_{\text{healthy},i}} \right]^2 + \left[ \frac{SE_{\text{healthy},i}}{X_{\text{healthy},i}} \right]^2 \]  

(2)

The sample standard deviations of the ratios \((SD_i)\) are calculated using the same approach. The population mean value \((WX)\) and population standard deviations \((SD)\) of ratios from \(N\) individual studies are estimated as follows using the reciprocal of standard error-weighted mean\(^{26}\) and pooled variance\(^{27}\)

\[ WX = \frac{\sum_{i=1}^{N} \frac{1}{SE^2_i} \cdot R_i}{\sum_{i=1}^{N} \frac{1}{SE^2_i}} \]  

(3)

\[ SD^2 = \frac{\sum_{i=1}^{N} (n_i - 1) \cdot SD_i^2}{\sum_{i=1}^{N} (n_i - 1)} \]  

(4)

where \(n_i\) typically indicates the sample size in study \(i\). In the clinical studies, \(n_i\) was reported for the participants in the healthy and the cirrhotic groups. However, in our analysis, which relies on ratios, we approximated \(n_i\) as the average number of healthy and cirrhotic participants in each study.

**Plasma fraction unbound.** Plasma fraction unbound \((fu,p)\) of bosentan, repaglinide, telmisartan, and valsartan have been reported for healthy individuals.\(^{18,24}\) The in-house value of \(fu,p\) for olmesartan was used. Assuming the unbound albumin concentration \(\left( C_{\text{albumin}} \right)\) is approximately equal to the total albumin concentration \(\left( C_{\text{albumin},\text{total}} \right)\), \(fu,p\) values for patients with liver cirrhosis are estimated based on a previously published approach.\(^{28}\)

\[ fu,p,\text{cirrhosis} = \frac{1}{fu,p,\text{healthy} \cdot \frac{C_{\text{albumin},\text{total}}}{C_{\text{albumin}}} + 1} \]  

(5)

**Blood to plasma ratio.** Blood to plasma ratio \((RB/P)\) is defined as:

\[
RB/P = \frac{C_B}{C_P} = \frac{C_E \cdot V_E + C_P \cdot V_P}{V_B} \cdot \frac{1}{C_P} = \frac{C_E \cdot HCT \cdot V_E + C_P \cdot (1 - HCT) \cdot V_B}{V_E \cdot C_P} = \frac{C_E}{C_P} \cdot HCT + 1 - HCT
\]  

(6)

where \(C\) and \(V\) represent concentration and volume; \(B, E,\) and \(P\) represent blood, erythrocyte, and plasma; and \(HCT\) represents hematocrit (\(Table 3\)). The reported \(RB/P\) values for bosentan, repaglinide, and valsartan in healthy individuals are 0.48, 0.48, 0.55, and 0.545,\(^{18}\) which would result in \(C_E/C_P\) less than zero. Hence, for these compounds \(C_E/C_P\) is fixed at zero, indicating very limited accumulation of these compounds in the erythrocyte. \(RB/P\) of olmesartan is not reported; however, the compound does not penetrate red blood cells,\(^{23}\) hence \(C_E/C_P\) is also fixed at zero. For telmisartan, \(C_E/C_P\) is reported to be 0.5,\(^{30}\) and assumed to be constant and independent of disease conditions.

**Tissue to plasma partition coefficient.** The tissue to plasma partition coefficients \((Kp)\) for nonliver tissues are calculated using an in silico method reported previously,\(^{31}\) under different disease conditions. In the \(Kp\) calculation, \(fu,p\) and \(RB/P\) values are calculated above, \(pKa\) and \(\log DT_{4,\text{a}}\) values are in \(Table 1\). For telmisartan, \(Kp\) values are derived from human positron emission tomography (PET) data\(^{24}\) due to known misprediction made by in silico methods.

**Blood flow.** Tissue blood flows are modeled as fractions of cardiac output. The cardiac output, portal vein, splenic vein, and liver arterial blood flow under liver cirrhosis conditions are adjusted using values given in \(Table 3\). Blood flows in other tissues are also adjusted accordingly such that the sum of blood flow fractions contributed by the tissues is 1.

**Renal clearance.** Renal clearance \((CL_R)\) of prodru of olmesartan (olmesartan medoxomil) under healthy and cirrhosis conditions has been reported.\(^{29}\) Since \(CL_R\) has not been reported for olmesartan, we assume that \(CL_R\) values of olmesartan and its prodrug are the same considering the fast conversion from produg to olmesartan in the human body.\(^{29}\) There is no reported \(CL_R\) of valsartan under conditions of cirrhosis but only for healthy individuals.\(^{25}\) Hence the ratios of valsartan \(CL_R\) between healthy and cirrhotic conditions are estimated as the weighted mean values of rosvastatin and olmesartan (0.85 and 0.79 for CP-A and B groups, see \(Supplemental Materials\)).\(^{11,29}\) Alternatively, assuming changes in \(CL_R\) in cirrhosis are similar to those for glomerular filtration rate \((GFR)\), valsartan \(CL_R\) can be predicted using ratios for GFR changes in the previous meta-analysis (0.70 and 0.58 for CP-A and B in ref. 5). However, such an approach leads to greater changes in \(CL_R\) than observed for rosvastatin and olmesartan.\(^{11,29}\) The pharmacokinetics of rosvastatin in healthy\(^{11}\) and liver cirrhosis individuals\(^{11}\) have been published; however, under cirrhotic conditions derived pharmacokinetic parameters but not concentration–time course are reported. As such, rosuvastatin is not included in this study, because of the additional challenge in estimating absorption and hepatic clearance without time-course data. We assume there is no renal excretion for the other three compounds.\(^{18,24}\) The unbound renal clearance \((CL_{R,U})\) is calculated using reported or estimated clinical renal clearance assuming well-stirred conditions as described before:\(^{18}\)

\[ CL_{R,U} = \frac{CL_R}{RB/P} \cdot \frac{fu,p}{fu,p - 1} \]  

(7)

where \(Q_{\text{renal-blood}}\) is renal blood flow.

**Hepatic clearance.** \(CL_{\text{bile}}\) and \(CL_{\text{net}}\) of bosentan, repaglinide, and valsartan, \(CL_{\text{net}}\) of bosentan and repaglinide, as well as \(CL_{\text{bile}}\) of olmesartan and valsartan for healthy individuals are estimated by fitting the model to the observed
Table 1 Compound-specific parameters for healthy individuals

| Compound     | Bosentan | Repaglinide | Telmisartan | Valsartan | Olmesartan |
|--------------|----------|-------------|-------------|-----------|------------|
| pKa          | 5.2      | 4.4 (acidic)| 3.8         | 4.6 (acidic)| 4.14       |
| logD<sub>7.4</sub> | 6.1 (basic) | 2.1         | 2.5         | 3.8 (acidic)|           |
| f<sub>u,r</sub> | 0.0053   | 0.0074      | 0.0050      | 0.0015    | 0.0045     |
| R<sub>u,p</sub> | 0.58     | 0.58        | 0.79        | 0.58      | 0.58       |
| R<sub>u,liver</sub> | 0.018    | 0.015       | 0.013       | 0.048     | 0.0090     |
| CL<sub>act</sub> | 0        | 0           | 0           | 0.62      | 0.60       |
| CL<sub>bile</sub> | 4,400     | 12,000      | 31,000      | 1,300     | 290 (250, 330) |
| CL<sub>pass</sub> | 11       | 120         | 70          | 0.46      | 1.3 (0.53, 2.1) |
| CL<sub>met</sub> | 11       | 120         | 530         | 0         | 0          |
| V<sub>max</sub> | 41,000   | —           | —           | 70,000    | —          |
| K<sub>m</sub> | 16,000   | —           | —           | 27,000    | —          |
| f<sub>a</sub> | 0.95     | 1.0         | 0.86        | 0.32      | —          |

**a** Except for olmesartan and telmisartan, values are reported in ref. 18.

**b** All values are reported in ref. 19 except for olmesartan, for which f<sub>u,liver</sub> is predicted using the method described in ref. 18.

**c** CL<sub>bile</sub> of valsartan and olmesartan are reported in refs. 29, 32.

**d** These estimates are derived as described in the method section.

**e** The values for telmisartan hepatic clearances are reported previously, while absorption parameters are reestimated using healthy individuals reported in the liver cirrhosis pharmacokinetic study. For glucuronidation, CL<sub>bile</sub> is 62 L/h, and f<sub>u,rep</sub> is 0.0073.

**f** CL<sub>pass</sub>, CL<sub>act</sub>, and CL<sub>met</sub> of olmesartan in healthy individuals are estimated by fitting observed plasma PK data without boundaries based on SCHH study. The values given in parentheses for healthy individuals are the 95% confidence intervals approximated by a bootstrap method. logD<sub>7.4</sub> and f<sub>u,r</sub> value of olmesartan are in house data, while pKa has been published before.

All values are rounded to two significant figures.

---

plasma concentration time profiles after intravenous dosing. CL<sub>met</sub> of olmesartan and valsartan, and CL<sub>bile</sub> of repaglinide are fixed at zero. CL<sub>bile</sub> of bosentan is fixed at a previously predicted value using sandwich-cultured human hepatocyte (SCHH). We simultaneously estimate CL<sub>pass</sub>, CL<sub>act</sub>, CL<sub>met</sub> (or CL<sub>bile</sub>) by fitting the clinical data for each compound individually, the model may be over-parameterized as described before, leading to unreliable estimates. On the other hand, if we fix CL<sub>pass</sub>, CL<sub>act</sub>, CL<sub>met</sub>, and CL<sub>bile</sub> at SCHH predicted values given in a previous study, there are substantial discrepancies between simulations and data. We want to minimize such discrepancies, since the following simulations and predictions for cirrhotic patients rely on the accuracy of simulation for healthy individuals. To address these issues, CL<sub>pass</sub>, CL<sub>act</sub>, CL<sub>met</sub>, and CL<sub>bile</sub> are estimated by fitting plasma concentration time profiles of each compound individually; however, they are bounded by their confidence intervals obtained in the previous study (i.e., in vitro SCHH (or human liver microsome, HLM) clearance × physiological scaling factor × confidence intervals of empirical scaling factors). The details of the estimation of the confidence intervals are given in the original publication. CL<sub>pass</sub>, CL<sub>act</sub>, CL<sub>met</sub>, and CL<sub>bile</sub> used for telmisartan prediction under healthy conditions are fixed at values given in the previous study due to the good agreement between data and simulations. There is no published SCHH data of olmesartan, hence its CL<sub>pass</sub>, CL<sub>act</sub>, and CL<sub>bile</sub> are estimated by fitting observed plasma concentration time course without boundaries based on SCHH. To assess the variability of the estimates, confidence intervals for CL<sub>pass</sub>, CL<sub>act</sub>, and CL<sub>bile</sub> are approximated by using a residual bootstrap method as described before. Bootstrap is not performed for other compounds because their fitting has been bounded by confidence intervals generated previously.

Passive permeability of the compound is assumed to be independent of the disease status, hence CL<sub>pass</sub> under cirrhosis conditions is assumed to be only affected by the functional liver mass.

$$\text{CL}_{\text{pass, cirrhosis}} = \text{CL}_{\text{pass, healthy}} \cdot R_{\text{liver mass}}$$

where $R_{\text{liver mass}}$ is the fraction of the functional liver size in healthy control.

CL<sub>met</sub> under liver cirrhosis conditions is assumed to be decreased due to both reduced functional liver mass and the reduced metabolic enzyme activity as described previously.

$$\text{CL}_{\text{met, cirrhosis}} = \text{CL}_{\text{met, healthy}} \cdot R_{\text{liver mass}} \cdot \sum_{i=1}^{n} \left( R_{\text{metabolism, } i} \right)$$

where $R_{\text{metabolism}}$ is the ratio of metabolic enzyme activity between the diseased group and the healthy control, $i$ represents each metabolic enzyme, and $n$ is the number of metabolic enzymes. According to previous HLM studies, 60% of dosed bosentan is metabolized through CYP3A4, and the remaining 40% metabolized through CYP2C9, while 63% of repaglinide is metabolized by CYP2C8, 18% by CYP3A4, and 19% by UDP-glucuronosyltransferase (UGT). Telmisartan is...
metabolized exclusively by UGT.\textsuperscript{35} We used reported $R_{\text{metabolism}}$ of CYP3A4, CYP2C8, and CYP2C9 activity in CP-A, CP-B, and CP-C groups,\textsuperscript{5} The UGT activity is assumed to be not affected by liver cirrhosis as suggested by a previous study.\textsuperscript{36} Similar to $CL_{\text{met}}$, in this study $CL_{\text{act}}$ and $CL_{\text{bile}}$ are assumed to depend on both functional liver mass and the transporter activity.

$$CL_{\text{act}, \text{cirrhosis}} = CL_{\text{act, healthy}} \cdot R_{\text{liver mass}} \cdot \sum_{i=1}^{n} (F_{\text{active transporter}, i} \cdot R_{\text{active transporter}, i})$$  \hspace{1cm} (10)

$$CL_{\text{bile, cirrhosis}} = CL_{\text{bile, healthy}} \cdot R_{\text{liver mass}} \cdot \sum_{i=1}^{n} (F_{\text{biliary transporter}, i} \cdot R_{\text{biliary transporter}, i})$$

where $F_{\text{transporter}}$ is the fraction of each transporter made to $CL_{\text{act}}$ (or $CL_{\text{bile}}$), and $R_{\text{transporter}}$ is the ratio of transporter
activity between the diseased group and the healthy control. $R_{\text{transporter}}$ has been reported using mRNA measurements but the diseased individuals were not assessed based on the Child–Pugh classification system (Table 3),\textsuperscript{37,38} hence in the prospective predictions (Method 1), we assume the three disease groups have the same $R_{\text{transporter}}$ and standard deviation. $F_{\text{transporter}}$ has been reported for olmesartan (OATP1B1, 0.53; OATP1B3, 0.47; no OATP2B1 and NTCP

Figure 1 The observed and simulated mean plasma concentration time profiles in healthy individuals of (a) bosentan (10 mg 5-minute intravenous infusion and 125 mg oral dosing), (b) olmesartan (8 mg intravenous bolus dosing), (c) repaglinide (2 mg 15-minute intravenous infusion and 4 mg oral dosing), (d) telmisartan (40 mg 20-minute intravenous infusion and 40 mg oral dosing), and (e) valsartan (20 mg intravenous bolus and 160 mg oral dosing). The blue circles and solid lines represent the observations and simulations following intravenous dosing. The red squares and dashed lines represent the observations and simulations following oral dosing. The simulations are performed with parameter values for healthy individuals given in Table 1.
uptake\textsuperscript{39,40}) but not for the other four compounds, hence for other compounds $F_{\text{transporter}}$ are generated randomly from a uniform distribution.

Assuming liver cirrhosis has a similar impact on all uptake transporters, $R_{\text{transporter}}$ values of CP-A and CP-B are estimated by fitting observed concentration–time
Drug absorption. The absorption parameters \( k_a \) (or \( V_{\text{max}} \)) and \( F_a \) are estimated by fitting the observed plasma concentration–time profiles following oral dosing from healthy individuals in the liver cirrhosis studies,8–12 simultaneously with \( CL_{\text{pass}} \), \( CL_{\text{act}} \), \( CL_{\text{met}} \) and \( CL_{\text{bile}} \) estimation by fitting intravenous data from healthy individuals as described above (with the exception of telmisartan fitting, where all parameters except for \( k_a \) and \( F_a \) are fixed as described above). Due to the lack of intestinal transporter data under cirrhotic conditions at this time, assuming liver is the major disposition organ, and no change of the intestinal transporter activity, the absorption parameters are kept the same for the healthy and liver cirrhosis groups. Absorption parameters are not estimated for olmesartan, because the human pharmacokinetic study including individuals with cirrhosis was performed following intravenous bolus dosing.29

Simulations of pharmacokinetics under liver cirrhotic conditions

Assuming all parameters are independent of each other and follow normal distributions, the values of albumin concentrations as the fraction of healthy control are randomly generated from a normal distribution with mean and standard deviation in Table 3, as are values of other parameters with relatively high sensitivity coefficients including HCT values, cardiac output, portal vein blood flow, splenic vein blood flow, liver arterial blood flow, functional liver size, and hepatic transporter activity. For a few parameters with standard deviations of a similar magnitude as the mean values, negative values may be generated occasionally but were discarded. With generated parameter values, concentration–time profiles are simulated using the PBPK model.

RESULTS

Published plasma time course data in healthy individuals and cirrhotic patients for liver transporter substrates bosen-
We established a PBPK model to simulate how liver cirrhosis affects the pharmacokinetics of liver transporter substrates. A major challenge is that the effect of liver cirrhosis on the in vivo transporter activity is unknown. Although previous studies have reported that liver cirrhosis may change mRNA and protein expression levels, it is unclear...
For bosentan and telmisartan, the observed AUCs are reported as arithmetic mean values, as are the simulated AUCs. For bosentan, the observed AUCs are reported as geometric mean values, as are the simulated AUCs. For the other four compounds, the observed AUCs are reported up to 96, 48, and 36 hours, respectively, as are the simulations.

Method 2 represents the single simulations with fitted parameters, contributions of individual transporters made to total uptake are randomly generated from a uniform distribution, and other parameters listed in Table 3 are randomly generated using reported mean and standard deviations. Method 2 represents the single simulations with fitted transporters, and other parameters listed in Table 3 fixed at their mean values. The prediction intervals are approximated using the same method as Method 1 except that Rtransporter were prepared with residual bootstrap results.

For bosentan, the observed AUCs are reported as geometric mean values, as are the simulated AUCs. For the other four compounds, the observed AUC are reported as arithmetic mean values, as are the simulations. For the other four compounds, the observed AUCs are reported as AUC0–∞, as are the simulations. For olmesartan, repaglinide, and valsartan, the observed AUCs are reported up to 96, 48, and 36 hours, respectively, as are the simulations.

whether changes in transporter expression levels due to liver disease can be directly translated into pharmacokinetics in patients.

We initially prospectively predicted the change of in vivo liver transporter activity (Rtransporter) using mRNA data. The mean predictions can more reasonably match mean observations from the CP-A than CP-B groups. This might arise if more mRNA samples in these studies were taken from CP-A patients.37,38 To improve prediction accuracy, transporter mRNA or protein expression data classified using the Child–Pugh system would be highly desirable in the future. In addition, because the fractional contributions that transporters made to the total uptake are unknown, they are randomly generated in this analysis. This leads to additional uncertainty in predictions. Several different in vitro assays have been developed to deconvolute the contribution made by individual transporters to the overall uptake.17 It could be useful to incorporate these data into the model once they are available. The Rtransporter value may also be predicted using experimentally determined protein expression levels, but would be only slightly less than the value estimated from mRNA data.37 In this model, because we assumed that all parameters in Table 1 follow normal distributions and are independent of each other, the variability of the simulations may be overpredicted. However, the approximated variability is in general comparable to the observed variability (Table 4 and Figure 2).

To better describe the data, we reestimated Rtransporter for the CP-A and CP-B groups by fitting the observed pharmacokinetics and assuming all uptake transporters are similarly affected in the diseased conditions. As expected, the fitted value for CP-A groups (0.78) is similar to the mRNA-predicted values for uptake transporters (0.65 for OATP1B1, 0.73 for OATP1B3, and 0.77 for OATP2B1); however, the fitted value for the CP-B groups (0.31) is lower than these mRNA-predicted values. This top-down fitting approach provides an alternative method to the mRNA-predicted Rtransporter. The advantage of the top-down approach is to characterize the impact of cirrhosis on the transporter activity based on the CP system, which is not available from current mRNA data. The two approaches should be further tested when data for more compounds are available.

We assumed that the differences were due to liver transporter parameters, but given the very similar results with IV olmesartan and a lack of data on intestinal changes, we cannot rule out as an alternative hypothesis that absorption is affected to varying degrees in the diseased patients.

Additionally, liver cirrhosis has a pronounced impact on the observed pharmacokinetics of some compounds (e.g., valsartan) but not others (e.g., olmesartan), which makes it challenging to use a unique Rtransporter value to describe the change in the pharmacokinetics of all the compounds. It may be that the Child–Pugh score is not an accurate enough indicator of hepatic function, considering the score is not directly assessed on liver function. For example, a large body of conflicting literature on changes in hepatic blood flows in cirrhosis have been generated based on the Child–Pugh classification,5 indicating that under the current paradigms, the Child–Pugh score cannot properly reflect the physiological changes.

Table 4 Observed and simulated AUCplasma (mean and 95% prediction interval)

| Compound          | Method 1   | Method 2   |
|-------------------|------------|------------|
|                   | Observations | Simulations | Simulations |
| Bosentan Healthy  | 11957 (1803, 23035) | 8313 | 8313 |
| CP-A              | 10781 (1577, 20931) | 13389 (4870, 45698) | 12825 (6811, 32887) |
| Olmesartan Healthy | 5964 (3657, 8271) | 4811 | 4811 |
| CP-A              | 6780 (0, 15640) | 5795 (2698, 12648) | 5294 (3457, 10907) |
| CP-B              | 6972 (4093, 9851) | 4965 (2256, 13245) | 7394 (3686, 17451) |
| Repaglinide Healthy | 92 (0, 245) | 62 | 62 |
| CP-B              | 369 (0, 903) | 173 (32, 694) | 303 (129, 910) |
| Telmisartan Healthy | 471 (0, 1282) | 392 | 392 |
| CP-A              | 1290 (0, 4060) | 785 (49, 3079) | 766 (83, 3762) |
| Valsartan Healthy | 21200 (6309, 36091) | 21640 | 21640 |
| CP-A              | 46800 (25698, 67902) | 26817 (11829, 52989) | 25568 (15995, 47824) |
| CP-B              | 45400 (37827, 52973) | 25436 (10618, 53145) | 39796 (19739, 72470) |

AUCs of healthy individuals are generated using values given in Table 1. 95% prediction intervals of observations are estimated using reported standard deviations and t statistic, and prediction intervals of simulations are approximated using 2.5 and 97.5 percentile of 1000 simulations.

Table 1

| Compound          | Method 1   | Method 2   |
|-------------------|------------|------------|
|                   | Observations | Simulations | Simulations |
| Bosentan Healthy  | 11957 (1803, 23035) | 8313 | 8313 |
| CP-A              | 10781 (1577, 20931) | 13389 (4870, 45698) | 12825 (6811, 32887) |
| Olmesartan Healthy | 5964 (3657, 8271) | 4811 | 4811 |
| CP-A              | 6780 (0, 15640) | 5795 (2698, 12648) | 5294 (3457, 10907) |
| CP-B              | 6972 (4093, 9851) | 4965 (2256, 13245) | 7394 (3686, 17451) |
| Repaglinide Healthy | 92 (0, 245) | 62 | 62 |
| CP-B              | 369 (0, 903) | 173 (32, 694) | 303 (129, 910) |
| Telmisartan Healthy | 471 (0, 1282) | 392 | 392 |
| CP-A              | 1290 (0, 4060) | 785 (49, 3079) | 766 (83, 3762) |
| Valsartan Healthy | 21200 (6309, 36091) | 21640 | 21640 |
| CP-A              | 46800 (25698, 67902) | 26817 (11829, 52989) | 25568 (15995, 47824) |
| CP-B              | 45400 (37827, 52973) | 25436 (10618, 53145) | 39796 (19739, 72470) |

AUCs of healthy individuals are generated using values given in Table 1. 95% prediction intervals of observations are estimated using reported standard deviations and t statistic, and prediction intervals of simulations are approximated using 2.5 and 97.5 percentile of 1000 simulations.

Method 1 represents 1000 simulations with mRNA-derived Rtransporter contributions of individual transporters made to total uptake are randomly generated from a uniform distribution, and other parameters listed in Table 3 are randomly generated using reported mean and standard deviations. Method 2 represents the single simulations with fitted Rtransporter, and other parameters listed in Table 3 fixed at their mean values. The prediction intervals are approximated using the same method as Method 1 except that Rtransporter were prepared with residual bootstrap results.

For bosentan, the observed AUCs are reported as geometric mean values, as are the simulated AUCs. For the other four compounds, the observed AUC are reported as arithmetic mean values, as are the simulated AUCs. For the other four compounds, the observed AUCs are reported as AUC0–∞, as are the simulations. For olmesartan, repaglinide, and valsartan, the observed AUCs are reported up to 96, 48, and 36 hours, respectively, as are the simulations.

www.wileyonlinelibrary/psp4
due to cirrhosis. On the other hand, although not reflected in the mRNA data, it is also possible that the disease can more significantly affect the activity of some transporters than others. As such, because the contribution each transporter makes to the total hepatic uptake varies for different compounds, liver cirrhosis could also have different impacts on these compounds. To test this hypothesis, we assumed that there are type-1 and type-2 uptake transporters responsible for the hepatic uptake of these compounds that have different \( R_{\text{transporter}} \) values, and estimated parameters by fitting the clinical observations. This alternative analysis resulted in improved agreement between the mean simulations and observations (data not shown) for valsartan. However, the improvement is not significant for other drugs. Furthermore, such an approach is not practical to apply as a prospective prediction because of the lack of information about the contributions each transporter made to the total uptake.

In conclusion, a PBPK model for liver transporter substrates to simulate pharmacokinetics under liver cirrhosis conditions was established, and a meta-analysis was performed to obtain system-dependent parameters. This model can be useful in understanding the changes in the liver transporter activity due to cirrhosis and may aid in predicting systemic and potentially liver exposure of the liver transporter substrates under cirrhotic conditions in the future.

Acknowledgments. The authors thank Dr Veena Somayaji (Pfizer) and Dr Vinicius Bonato (Pfizer) for helpful discussions about statistical meta-analysis.

Author Contributions. R.L., H.B., and T.M. wrote the article; R.L., H.B., and T.M. designed the research; R.L. performed the research; R.L. analyzed the data.

Conflict of Interest. The authors declare no conflicts of interest.

1. Schuppan, D. & Afdhal, N.H. Liver cirrhosis. Lancet 371, 838–851 (2008).
2. Rodighiero, V. Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinet. 37, 399–431 (1999).
3. Jones, H. & Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT: Pharmacometrics Syst. Pharmacol. 2, e63 (2013).
4. Edgerton, A.N. & Willmann, S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47, 743–752 (2008).
5. Johnson, T.N., Boustery, K., Rowland-Yeo, K., Tucker, G.T. & Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49, 189–206 (2010).
6. Strougo, A., Yassen, A., Krauwinkel, W., Danhof, M. & Freijer, J. A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions. Drug Metab. Dispos. 39, 1278–1287 (2011).
7. Wilkinson, G.R. & Shand, D.G. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18, 377–390 (1975).
8. Brockman, L.J. et al. Pharmacokinetics of valsartan in patients with liver disease. Clin. Pharmacol. Ther. 62, 272–278 (1997).
9. Hatov, V., Walker, K.H., Christensen, M.S. & Haug-Pihale, G. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J. Clin. Pharmacol. 40, 142–152 (2000).
10. Stangier, J., Su, C.A., Schondorfer, G. & Roth, W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J. Clin. Pharmacol. 40, 1355–1364 (2000).
11. Simonson, S.G., Martin, P.D., Mitchell, P., Schnick, D.W., Lasseter, K.C. & Warwick, M.J. Pharmacokinetics and pharmacodynamics of rosvastatin in subjects with hepatic impairment. Eur. J. Clin. Pharmacol. 58, 669–675 (2003).
12. van Giersbergen, P.L., Popescu, G., Bodin, F. & Dingemanse, J. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosantan, a dual endothelin receptor antagonist. J. Clin. Pharmacol. 43, 15–22 (2003).
13. Weber, C. et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosantan in healthy human subjects. Clin. Pharmacol. Ther. 60, 124–137 (1996).
14. Auletta, M., Oliverio, U., Iasciolo, L., Scherillo, G. & Antoniello, S. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. Angiology 51, 1013–1020 (2000).
15. Hatop, V., Oliver, S. & Su, C.A. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. 36, 636–641 (1998).
16. Tolman, K.G., Fonseca, V., Dalpiaz, A. & Tan, M.H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabet. Care 30, 734–743 (2007).
17. Li, R., Barton, H. & Varma, M. Prediction of pharmacokinetics and drug–drug interactions when hepatic transporters are involved. Clin. Pharmacokinet. 1–20 (2014).
18. Jones, H.M. et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab. Dispos. 40, 1007–1017 (2012).
19. Li, R. et al. A middle-out approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling. J. Pharmacokinet. Pharmacodyn. 41, 197–209 (2014).
20. Poirier, A., Cascais, A.C., Funk, C. & Lave, T. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J. Pharmacokinet. Pharmacodyn. 36, 585–611 (2009).
21. Watanabe, T., Kusuhara, H., Maeda, K., Shiota, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652–662 (2009).
22. Pfeifer, N.D., Bridges, A.S., Ferslew, B.C., Hardwick, R.N. & Brouwer, K.L. Hepatic basolateral efflux contributes significantly to rosvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J. Pharmacol. Exp. Ther. 347, 737–745 (2013).
23. Pfeifer, N.D., Yang, K. & Brouwer, K.L. Hepatic basolateral efflux contributes significantly to rosvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J. Pharmacol. Exp. Ther. 347, 727–736 (2013).
24. Li, R., Ghosh, A., Maurer, T.S., Kimoto, E. & Barton, H.A. Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human. Drug Metab. Dis. e-pub ahead of print 2014.
25. Hoford, N.H., Ambros, R.J. & Stoeckel, K. Models for describing absorption rate and estimating extent of bioavailability: application to cetefamid pivoxil. J. Pharmacokin. Biopharm. 20, 421–442 (1992).
26. Hedges, L.V. Meta-analysis. J. Educ. Behav. Stat. 17, 279–296 (1992).
27. Cooper, J.H. & Mosteller, F. An alternative to null-hypothesis significance tests. Psychol. Sci. 16, 345–353 (2005).
28. Kalvass, J.C. & Maurer, T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dis. 23, 327–338 (2002).
29. U.S. Food and Drug Administration & Center for Drug Evaluation and Research. Benicar NDA 21–286 Clinical Pharmacology Biopharmaceutics Review. (2002).
30. Stangier, J. et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J. Clin. Pharmacol. 40, 1312–1322 (2000).
31. Rodgers, T. & Rowland, M. Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238–1257 (2006).
32. Flesch, G., Muller, P. & Lloyd, P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur. J. Clin. Pharmacol. 52, 115–120 (1997).
33. Dingemanse, J. & van Giersbergen, P.L. Clinical pharmacology of bosantan, a dual endothelin receptor antagonist. Clin. Pharmacokin. 43, 1089–11015 (2004).
34. Sahl, C., Houston, J.B. & Gaitelid, A. A comprehensive assessment of repaglinide metabolite pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab. Dispos. 40, 1279–1289 (2012).
35. Sahl, C., Houston, J.B. & Gaitelid, A. A comprehensive assessment of repaglinide metabolite pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab. Dispos. 40, 1279–1289 (2012).
36. Wiesen, W. et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc. Drug Rev. 18, 127–154 (2000).
37. Strassburg, C.P. et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50, 255–265 (2002).
37. Zollner, G. et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 38, 717–727 (2003).
38. Ogasawara, K. et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab. Pharmacokinet. 25, 190–199 (2010).
39. Yamada, A. et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab. Dispos. 35, 2166–2176 (2007).
40. Nakagomi-Hagihara, R. et al. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab. Dispos. 34, 862–869 (2006).

Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.wileyonlinelibrary.com/psp4)